Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADCOM Roaster announced
https://www.fda.gov/advisory-committees/cardiovascular-and-renal-drugs-advisory-committee/cardiovascular-and-renal-drugs-advisory-committee-roster
Appreciate your feedback on the panel members
Baker Brothers Make $1.4 Billion in Two Weeks on Biotech
https://www.bloomberg.com/news/articles/2019-11-01/baker-brothers-turn-biotech-prowess-into-a-3-8-billion-fortune
V Ref Market Share: 54.90% vs 54.40% --- ATH
My bad, typo mistake
Thanks cbb for spotting this
NORMALIZED Scripts Update for Week Ending 25/10
ATH Across the Board in Numbers & Market Share
V
TRx: 73,930 {vs 71,927; +2.79%} Sector +1.63% --- (8,871,654 vs 8,631,194) --- ATH
NRx: 34,405 {vs 32,917; +4.52%} Sector +3.06% --- (4,128,616 vs 3,949,996) --- ATH
Ref: 39,525 {vs 39,010; +1.32%} Sector +0.40% --- (4,743,038 vs 4,681,198) --- ATH
GenL
TRx: 60,872 {vs 60,582; +0.48%} (7,304,660 vs 7,269,820)
NRx: 28,910 {vs 28,450; +1.61%} (3,469,153 vs 3,414,044)
L
TRx: 853 {vs 970; -12.06%} (102,395 vs 116,437)
NRx: 342 {vs 398; -14.10%} (41,016 vs 47,747)
V TRx Market Share: 54.50% vs 53.89% ATH
V NRx Market Share: 54.05% vs 53.29% ---ATH
V Ref Market Share: 53.44% vs 53.48% ---ATH
For those interested in Old Scripts Numbers ATH Across the Board in Numbers & Market Share (except Refills 2nd ATH Market Share);
V TRx 56,008 vs GL TRx 46,038 & L 585 -- ATH
V NRx 22,424 vs GL NRx 19,297 & L 201 -- ATH
V Refills 33,584 vs GL Refills 26,741 & L 384 -- ATH
Aegis Capital initiated Amarin (AMRN) coverage with Buy and target $23
Aegis Capital initiated Amarin (AMRN) coverage with Buy rating and price target $23
Issuance Date: 2019-10-31
Copyright 2019 Briefing.com, Inc.
FDA approves AstraZeneca diabetes drug for treating heart failure risk
FDA unequal treat between big pharma and new small/mid companies like AMRN
https://mobile.reuters.com/article/amp/idUSKBN1X00J5?utm_campaign=trueAnthem%3A%2BTrending%2BContent&utm_content=5dad728a4c15b80001487d83&utm_medium=trueAnthem&utm_source=twitter&__twitter_impression=true
JL
I agree with you but we need to keep in mind that what is on label (the broadest it can be) will surely help in sales. Not in the sense of Dr. prescribing habits, but in terms of insurance coverage. Getting a proper coverage will help tremendously in increasing sales.
Dr. will surely be prescribing V off label but will patient pay out of pocket or not, that's the question
So hopefully a clear and broad label will help put this issue (insurance coverage) to bed
Our DCF assumes an 11% WACC, consistent with our valuation of other biopharma companies in a similar stage of clinical development with an upcoming commercial launch,
9M-2019 vs. 9M-2018 NORMALIZED Retail ONLY Data
Again V having a huge Year-on Year Increase Across the Board + driving the whole sector up with it
V
TRx 9M-2019 vs 9M-2018 +75.26% – Sector +15.80%
NRx 9M-2019 vs 9M-2018 +87.25% – Sector +22.97%
Ref 9M-2019 vs 9M-2018 +65.48% – Sector +10.00%
Gen L
TRx 9M-2019 vs 9M-2018 -4.62%
NRx 9M-2019 vs 9M-2018 +0.81%
Ref 9M-2019 vs 9M-2018 -9.01%
L
TRx 9M-2019 vs 9M-2018 -81.84%
NRx 9M-2019 vs 9M-2018 -83.78%
Ref 9M-2019 vs 9M-2018 -80.27%
V 9M-2019 Retail TRx Market Share: 48.20% vs 31.85% in 9M-2018
V 9M-2019 Retail NRx Market Share: 48.68% vs 31.96% in 9M-2018
V 9M-2019 Retail Ref Market Share: 47.78% vs 31.76% in 9M-2018
Q3-2019 vs. Q3-2018 NORMALIZED Retail ONLY Data
Again Amazing Year-on Year Increase Across the Board + driving the whole sector up with it
V
TRx: 873,160 {vs 462,239; +88.90%} – Sector +20.85% --- ATH
NRx: 401,806 {vs 205,659; +95.37%} – Sector +25.32% --- ATH
Ref: 471,354 {vs 256,580; +83.71%} – Sector +17.24% --- ATH
Gen L
TRx: 796,620 {vs 885,549; -10.04%}
NRx: 372,673 {vs 398,003; -6.36%}
L
TRx: 13,547 {vs 45,164; -70.00%}
NRx: 5,227 {vs 18,528; -71.79%}
V Q3-2019 NORMALIZED Retail TRx Market Share: 51.87% vs 33.18% in Q3-2018 --- ATH
V Q3-2019 NORMALIZED Retail NRx Market Share: 51.53% vs 33.05% in Q3-2018 --- ATH
V Q3-2019 NORMALIZED Retail Ref Market Share: 52.16% vs 33.29% in Q3-2018 --- ATH
Q3-2019 vs. Q2-2019 NORMALIZED Retail ONLY Data
Great quarterly increase + driving the whole sector up with it
V
TRx: 873,160 {vs 762,695; +14.48%} – Sector +7.98% --- ATH
NRx: 401,806 {vs 365,563; +9.91%} – Sector +5.58% --- ATH
Ref: 471,354 {vs 397,132; +18.69%} – Sector +10.14% --- ATH
Gen L
TRx: 796,620 {vs 779,712; +2.17%}
NRx: 372,673 {vs 366,403; +1.71%}
L
TRx: 13,547 {vs 16,549; -18.14%}
NRx: 5,227 {vs 6,560; -20.31%}
V Q3-2019 NORMALIZED Retail TRx Market Share: 51.87% vs 48.92% in Q2-2019 --- ATH
V Q3-2019 NORMALIZED Retail NRx Market Share: 51.53% vs 49.50% in Q2-2019 --- ATH
V Q3-2019 NORMALIZED Retail Ref Market Share: 52.16% vs 48.41% in Q2-2019 --- ATH
September-2019 vs. September-2018 NORMALIZED Retail ONLY Data
Amazing Year-On-Year Increase Across the Board; 95% increase in TRx & 100% increase in NRx & 91% increase in Refills
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+24% TRx & ~+27% NRx & ~+21% Refills) and at the same time increasing its own Market Share
V
TRx: 293,311 {vs 150,200; +95.28%} – Sector +23.74% -- 2nd ATH
NRx: 134,073 {vs 66,992; +100.13%} – Sector +26.80% -- 2nd ATH
Ref: 159,238 {vs 83,209; +91.37%} – Sector +21.24% ATH
Gen L
TRx: 257,848 {vs 292,005; -11.70%}
NRx: 120,098 {vs 132,161; -9.13%}
L
TRx: 4,146 {vs 6,561; -36.80%}
NRx: 1,590 {vs 2,548; -37.60%}
V September-2019 NORMALIZED Retail ONLY TRx Market Share: 52.82% vs 33.47% in September-2018 --- ATH
V September-2019 NORMALIZED Retail ONLY NRx Market Share: 52.42% vs 33.21% in September-2018 --- ATH
V September-2019 NORMALIZED Retail ONLY Ref Market Share: 53.16% vs 33.68% in September-2018 --- ATH
Total Monthly NORMALIZED Retail ONLY Data September-2019
ATH Across the Board in Market Share
2nd ATH in TRx & NRx Numbers & ATH in Refills Numbers
V
TRx: 293,311 {vs 294,133; -0.28%} – Sector -1.56% -- 2nd ATH (35,197,312 vs 35,295,975)
NRx: 134,073 {vs 137,079; -2.19%} – Sector -2.94% -- 2nd ATH (16,088,753 vs 16,449,508)
Ref: 159,238 {vs 157,054; +1.39%} – Sector -0.35% ATH (19,108,559 vs 18,846,467)
Gen L
TRx: 257,848 {vs 265,953; -3.05%} (30,941,803 vs 31,914,319)
NRx: 120,098 {vs 124,959; -3.89%} (14,411,770 vs 14,995,068)
L
TRx: 4,146 {vs 4,023; +3.07%} (497,546 vs 482,711)
NRx: 1,590 {vs 1,482; +7.34%} (190,839 vs 177,792)
Monthly NORMALIZED Retail TRx Market Share: 52.82% vs 52.14% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 52.42% vs 52.02% --- ATH
Monthly NORMALIZED Retail Refills Market Share: 53.16% vs 52.25% --- ATH
For those interested in Old Scripts Numbers ATH Across the Board in Market Share & Refills Numbers – 2nd ATH in TRx & NRx Numbers
V TRx 224,784 vs GL TRx 194,726 & L 2,733 -- 2nd ATH
V NRx 87,865 vs GL NRx 80,694 & L 945 -- 2nd ATH
V Refills 136,919 vs GL Refills 114,032 & L 1,788 -- ATH
TRx +95.28% NRx +100.13%
Refills +91.37%
Sector growing tremendously TRx +23.74% NRx +26.80 Refills +21.24%
Just a teaser about September Retail Numbers and the above is September-2019 vs September-2018
Crunching the numbers to post September vs August // Sep-19 vs Sep-18 // Q3-19 vs Q3-18 // Q3-19 vs Q2-19 // 9M-2019 vs 9M-2018
Goldman Sachs initiated Amarin Corporation (AMRN) coverage with Neutral and target $17
Goldman Sachs initiated Amarin Corporation (AMRN) coverage with Neutral and target $17
Issuance Date: 2019-10-15
NORMALIZED Scripts Update for Week Ending 04/10
ATH Across the Board in Numbers
ATH in TRx & NRx Market Share, 3rd ATH in Refills Market Share
V
TRx: 71,091 {vs 70,007; +1.55%} Sector +1.45% --- (8,530,965 vs 8,400,806) --- ATH
NRx: 33,354 {vs 32,662; +2.12%} Sector +1.80% --- (4,002,500 vs 3,919,429) --- ATH
Ref: 37,737 {vs 37,345; +1.05%} Sector +1.14% --- (4,528,465 vs 4,481,377) --- ATH
GenL
TRx: 61,138 {vs 60,332; +1.34%} (7,336,568 vs 7,239,836)
NRx: 28,847 {vs 28,474; +1.31%} (3,461,677 vs 3,416,898)
L
TRx: 1,016 {vs 1,002; +1.43%} (121,978 vs 120,257)
NRx: 423 {vs 381; +10.90%} (50,722 vs 45,737)
V TRx Market Share: 53.35% vs 53.30% ATH
V NRx Market Share: 53.26% vs 53.09% ---ATH
V Ref Market Share: 53.44% vs 53.48% ---3rd ATH
For those interested in Old Scripts Numbers ATH Across the Board in Numbers & Market Share;
V TRx 54,752 vs GL TRx 46,421 & L 650 -- ATH
V NRx 21,997 vs GL NRx 19,484 & L 238 -- ATH
V Refills 32,755 vs GL Refills 26,937 & L 412 -- ATH
NORMALIZED Scripts Update for Week Ending 27/09
3rd ATH Across the Board in Numbers
ATH in NRx Market Share, 2nd ATH in TRx & Refills Market Share
V
TRx: 70,007 {vs 70,878; -1.10%} Sector -1.07% --- (8,400,806 vs 8,494,423) --- 3rd ATH
NRx: 32,662 {vs 33,102; -1.33%} Sector -1.42% --- (3,919,429 vs 3,972,195) --- 3rd ATH
Ref: 37,345 {vs 37,685; -0.90%} Sector -0.75% --- (4,481,377 vs 4,522,228) --- 3rd ATH
GenL
TRx: 60,332 {vs 61,006; -1.11%} (7,239,836 vs 7,320,738)
NRx: 28,474 {vs 28,915; -1.53%} (3,416,898 vs 3,469,826)
L
TRx: 1,002 {vs 963; +4.04%} (120,257 vs 115,587)
NRx: 381 {vs 385; -0.98%} (45,737 vs 46,198)
V TRx Market Share: 53.30% vs 53.32% ---2nd ATH
V NRx Market Share: 53.09% vs 53.05% ---ATH
V Ref Market Share: 53.48% vs 53.56% ---2nd ATH
For those interested in Old Scripts Numbers 3rd ATH Across the Board in Numbers, ATH in NRx Market Share, 2nd ATH in TRx & Refills Market Share;
V TRx 53,635 vs GL TRx 45,768 & L 659 -- 3rd ATH
V NRx 21,435 vs GL NRx 19,201 & L 224 -- 3rd ATH
V Refills 32,200 vs GL Refills 26,567 & L 435 -- 3rd ATH
SP
In my opinion $13.76 is a level that we need to watch if it will be broken or not (that is the low after adcom announcement) and $13.89 to be watched for the closing price (lowest close after announcement)
With the general market, i have a feeling that it will be hard to maintain these levels.
If those are breached, $11.78 52-week low will be in play and the lowest close of $12.41 (24-12-2018) can be used to bring down the price for the 50 million short share to cover
Let's see how it will settle today, but personally anything below $13.80 will be a good LONG TERM BUY & hold till the end of AMARIN
All the above is my personal opinion
Fibrates and Niacin
Following on Sharinky msg and using google to get brand and generic names for both Fibrates & Niacin, i managed to get script numbers for both.
The numbers are for Year 2018 & 8M in 2019. Well i still can't believe that they are being prescribed to this extent especially Fibrates and keep in mind that for 8M comparison between 2018 & 2019 Niacin Sector Numbers is down 26% and Fibrates Sector Numbers down 11%. Once V is approved and insurance is covering fully and with proper education and ads we should capture a big % of these 2.
Fibrates
Niacin
Important to read
I had some time to kill and decided to illustrate the normalized monthly scripts TRx & NRx since 2009 (it was only L at that time, so L = Sector) until August-2019 around 10Y
V was introduced in 2013, GL in 2014
You will see in the graphs below that V is steadily increasing the TRx sector back to levels not seen since 2009 and already surpassed the old levels of NRx.
TRx Graph
NRx Graph
NORMALIZED Scripts Update for Week Ending 20/09
The Scripts keeps on getting better and better
ATH Across the Board in Market Share & Numbers (except Refills 2nd ATH)
TRx almost 71,000 & NRx > 33,000
V
TRx: 70,878 {vs 70,559; +0.32%} Sector -0.68% --- (8,494,423 vs 8,467,050) ---ATH
NRx: 33,102 {vs 32,840; +0.80%} Sector -0.64% --- (3,972,195 vs 3,940,842) --- ATH
Ref: 37,685 {vs 37,718; -0.09%} Sector -0.72% --- (4,522,228 vs 4,526,208) --- 2nd ATH
GenL
TRx: 61,006 {vs 62,111; -1.78%} (7,320,738 vs 7,453,301)
NRx: 28,915 {vs 29,544; -2.13%} (3,469,826 vs 3,545,228)
L
TRx: 963 {vs 1,000; -3.65%} (115,587 vs 119,966)
NRx: 385 {vs 419; -8.21%} (46,189 vs 50,318)
V TRx Market Share: 53.32% vs 52.79% ---ATH
V NRx Market Share: 53.05% vs 52.29% ---ATH
V Ref Market Share: 53.56% vs 53.22% ---ATH
For those interested in Old Scripts Numbers ATH Across the Board in Market Share & Numbers (except Refills 2nd ATH);
V TRx 54,001 vs GL TRx 46,048 & L 648 -- ATH
V NRx 21,622 vs GL NRx 19,421 & L 224 -- ATH
V Refills 32,379 vs GL Refills 26,627 & L 424 -- ATH
NORMALIZED Scripts Update for Week Ending 13/09
ATH Across the Board in Numbers & Market Share
TRx > 70,000 & NRx ~ 33,000
Sector’s TRx & NRx & Refills at levels not seen since June-2013
V
TRx: 70,559 {vs 63,318; +11.44%} Sector +9.31% --- (8,467,050 vs 7,598,119) --- ATH
NRx: 32,840 {vs 27,532; +19.28%} Sector +16.18% --- (3,940,842 vs 3,303,855) --- ATH
Ref: 37,718 {vs 35,786; +5.40%} Sector +3.87% --- (4,526,208 vs 4,294,264) --- ATH
GenL
TRx: 62,111 {vs 58,040; +7.01%} (7,453,301 vs 6,964,784)
NRx: 29,544 {vs 26,210; +12.72%} (3,545,228 vs 3,145,165)
L
TRx: 1,000 {vs 926; +8.02%} (119,966 vs 111,060)
NRx: 419 {vs 316; +32.52%} (50,318 vs 37,969)
V TRx Market Share: 52.79% vs 51.78% ---ATH
V NRx Market Share: 52.29% vs 50.93% ---ATH
V Ref Market Share: 53.22% vs 52.45% ---ATH
For those interested in Old Scripts Numbers ATH Across the Board in Numbers & Market Share except NRx 2nd ATH in Market Share;
V TRx 53,972 vs GL TRx 46,942 & L 653 -- ATH
V NRx 21,521 vs GL NRx 19,964 & L 245 -- ATH
V Refills 32,451 vs GL Refills 26,978 & L 408 -- ATH
August-2019 vs. August-2018 NORMALIZED Retail ONLY Data
Amazing Year-On-Year Increase Across the Board; 85% increase in TRx & 93% increase in NRx & 79% increase in Refills
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+18% TRx & ~+22% NRx & ~+14% Refills) and at the same time increasing its own Market Share
V
TRx: 294,133 {vs 158,995; +85.00%} – Sector +17.80% -- ATH
NRx: 137,079 {vs 71,072; +92.87%} – Sector +22.42% -- ATH
Ref: 157,054 {vs 87,923; +78.63%} – Sector +14.04% ATH
Gen L
TRx: 265,953 {vs 312,961; -15.02%}
NRx: 124,959 {vs 141,557; -11.73%}
L
TRx: 4,023 {vs 6,870; -41.44%}
NRx: 1,482 {vs 2,626; -43.59%}
V August-2019 NORMALIZED Retail ONLY TRx Market Share: 52.14% vs 33.21% in August-2018 --- ATH
V August-2019 NORMALIZED Retail ONLY NRx Market Share: 52.02% vs 33.02% in August-2018 --- ATH
V August-2019 NORMALIZED Retail ONLY Ref Market Share: 52.25% vs 33.36% in August-2018 --- ATH
For those interested in Old Scripts Numbers Amazing Growth in Numbers & Market Share & ATH in both
V TRx +78.95% August-19 vs August-18 vs GL -18.66% & L -41.04% -- Sector +13.53% – Market Share 52.42% vs 33.26%
V NRx +83.28% August-19 vs August-18 vs GL -14.90% & L -43.62% -- Sector +17.00% – Market Share 51.39% vs 32.81%
V Refills +76.18% August-19 vs August-18 vs GL -21.15% & L -39.70% -- Sector +11.25% – Market Share 53.13% vs 33.55%
Total Monthly NORMALIZED Retail ONLY Data August-2019
Amazing Numbers – ATH Across the Board in Numbers & Market Share
Worth noting that the Sector is at new levels never seen since beginning 2014 & V is always increasing its Market Share
V
TRx: 294,133 {vs 285,716; +2.95%} – Sector +0.03% -- ATH (35,295,975 vs 34,285,926)
NRx: 137,079 {vs 130,654; +4.92%} – Sector +1.19% -- ATH(16,449,508 vs 15,678,430)
Ref: 157,054 {vs 155,062; +1.28%} – Sector -0.96% ATH (18,846,467 vs 18,607,496)
Gen L
TRx: 265,953 {vs 272,819; -2.52%} (31,914,319 vs 32,738,238)
NRx: 124,959 {vs 127,616; -2.08%} (14,995,068 vs 15,313,885)
L
TRx: 4,023 {vs 5,378; -25.21%} (482,711 vs 645,391)
NRx: 1,482 {vs 2,156; -31.27%} (177,792 vs 258,681)
Monthly NORMALIZED Retail TRx Market Share: 52.14% vs 50.67% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 52.02% vs 50.17% --- ATH
Monthly NORMALIZED Retail Refills Market Share: 52.25% vs 51.09% --- ATH
For those interested in Old Scripts Numbers Amazing Numbers – ATH Across the Board in Numbers & Market Share
V TRx 225,460 vs GL TRx 201,894 & L 2,741 -- ATH
V NRx 90,077 vs GL NRx 84,297 & L 897 -- ATH
V Refills 135,383 vs GL Refills 117,597 & L 1,844 -- ATH
NORMALIZED Scripts Update for Week Ending 06/09
Short Week
V
TRx: 63,318 {vs 68,640; -7.75%} Sector -6.77% --- (7,598,119 vs 8,236,789)
NRx: 27,532 {vs 31,888; -13.66%} Sector -11.40% --- (3,303,855 vs 3,826,598)
Ref: 35,786 {vs 36,752; -2.63%} Sector -2.74% --- (4,294,264 vs 4,410,191)
GenL
TRx: 58,040 {vs 61,584; -5.75%} (6,964,784 vs 7,390,057)
NRx: 26,210 {vs 28,814; -9.04%} (3,145,165 vs 3,457,718)
L
TRx: 926 {vs 937; -1.21%} (111,060 vs 112,422)
NRx: 316 {vs 313; +1.09%} (37,969 vs 37,558)
V TRx Market Share: 51.78% vs 52.33%
V NRx Market Share: 50.93% vs 52.26%
V Ref Market Share: 52.45% vs 52.39%
For those interested in Old Scripts Numbers;
V TRx 49,192 vs GL TRx 43,722 & L 618
V NRx 18,188 vs GL NRx 17,596 & L 204
V Refills 31,004 vs GL Refills 26,126 & L 414
Scripts
Sorry couldn't update the scripts and i few hundred posts behind...were the scripts updated? or i do that tomorrow morning?
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins
.....The NLA recommendation was issued as a Class I, Level B-R (STRONG) recommendation, its highest designation, for icosapent ethyl....
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190916:nGNXbmBhms
PDUFA Date Announced
As previously announced as expected the assigned PDUFA date is December 28, 2019.
https://www.sec.gov/ix?doc=/Archives/edgar/data/897448/000119312519243359/d818669d8k.htm
Proposed Indication: to reduce the risk of cardiovascular events, as an adjunct to statin therapy in adult patients with elevated triglycerides levels (135 mg/dL or greater) and other risk factors for cardiovascular disease, based on the results of a clinical study entitled “A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin.
The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)”
Sharinky,
I feel way better compared to the time when i was on statin alone.
No side effects i encountered. None at all, on the contrary those random joint pain i used to have when on statin alone totally vanished. A weird effect too, dunno if it is related, something i mentioned earlier on the board, i used to have dandruff and was using special anti-dandruff shampoo, since started V the dandruff disappeared and haven't used a special anti-dandruff shampoo since April-2019
Citi: Now an attractive time to buy Amarin shares
Citi analyst Joel Beatty continues to believe Amarin's Vascepa will likely be granted a cardiovascular risk reduction label shortly after the FDA panel meeting scheduled for November. This makes now an attractive time to buy the stock, Beatty tells investors in a research note. During a recent fireside chat, Amarin CEO John Thero highlighted two major upcoming sales inflection points, says the analyst. The first is the promotion of an expanded CV risk reduction label and the second is direct-to-consumer marketing, which the company expects to be able to begin six months after a label expansion, Beatty points out. The analyst believes this is likely to be a "powerful tool for patent education and physician education." He keeps a Buy rating on Amarin.
Read more at:
https://thefly.com/landingPageNews.php?id=2960032
Thanks
Blood Results -- Update
So around 20/02/2019 i did my blood tests and posted them on ihub and asked the opinion of Cardiologymd
I started back my medicine Crestor 20mg + V beginning of March-2019 and didnt change anything in my life style or food regime, nothing nothing at all.
Just did my follow up blood test and you will see below the huge change in numbers. Cholesterol level still a bit high, but im almost there. Same goes for my Triglycerides levels.
2 Years back when i was just on Crestor, the numbers didn't change that much, so V is having a major effect and that's my personal experience :):)
NORMALIZED Scripts Update for Week Ending 30/08
ATH Across the Board in Numbers
ATH in TRx Market Share – 2nd ATH in NRx & Refills Market Share
V
TRx: 68,640 {vs 66,510; +3.20%} Sector +3.16% --- (8,236,789 vs 7,981,216) --- ATH
NRx: 31,888 {vs 30,927; +3.11%} Sector +2.49% --- (3,826,598 vs 3,711,241) --- ATH
Ref: 36,752 {vs 35,583; +3.28%} Sector +3.75% --- (4,410,191 vs 4,269,975) --- ATH
GenL
TRx: 61,584 {vs 59,675; +3.20%} (7,390,057 vs 7,161,034)
NRx: 28,814 {vs 28,251; +1.99%} (3,457,718 vs 3,390,129)
L
TRx: 937 {vs 959; -2.31%} (112,422 vs 115,078)
NRx: 313 {vs 356; -12.05%} (37,558 vs 42,705)
V TRx Market Share: 52.33% vs 52.31% --- ATH
V NRx Market Share: 52.26% vs 51.95% --- 2nd ATH
V Ref Market Share: 52.39% vs 52.63% --- 2nd ATH
For those interested in Old Scripts Numbers ATH Across the Board in Numbers –– 2nd ATH Across the Board in Market Share;
V TRx 52,232 vs GL TRx 46,563 & L 646 -- ATH
V NRx 20,763 vs GL NRx 19,397 & L 198 -- ATH
V Refills 31,469 vs GL Refills 27,166 & L 448 -- ATH
AMRN CALLS
Interesting activity on 20 March 2020 Strike $20
So far 3,170 contracts traded and price increase 18.75% up to a premium of $2.60 so far
Deepak L. Bhatt: “Based on what we’re learning from REDUCE-IT and the related guidance from ESC and EAS, I foresee the beginning of a global change in clinical practice in how best to treat patients with multifactorial risks of cardiovascular events beyond cholesterol management.”
NORMALIZED Scripts Update for Week Ending 23/08
ATH in TRx Numbers & Refills – 2nd ATH in NRx Numbers
ATH in TRx & Refills Market Share – 2nd ATH in NRx Market Share
V
TRx: 66,510 {vs 65,855; +0.99%} Sector +0.46% --- (7,981,216 vs 7,902,656) --- ATH
NRx: 30,927 {vs 31,003; -0.24%} Sector +0.54% --- (3,711,241 vs 3,720,325) --- 2nd ATH
Ref: 35,583 {vs 34,853; +2.10%} Sector +0.40% --- (4,269,975 vs 4,182,331) --- ATH
GenL
TRx: 59,675 {vs 59,790; -0.19%} (7,161,034 vs 7,174,760)
NRx: 28,251 {vs 27,880; +1.33%} (3,390,129 vs 3,345,563)
L
TRx: 959 {vs 913; +5.08%} (115,078 vs 109,519)
NRx: 356 {vs 333; +6.78%} (42,705 vs 39,995)
V TRx Market Share: 52.31% vs 52.04% --- ATH
V NRx Market Share: 51.95% vs 52.36% --- 2nd ATH
V Ref Market Share: 52.63% vs 51.75% --- ATH
For those interested in Old Scripts Numbers ATH Across the Board in Numbers –– ATH in TRx & Refills Market Share – 2nd ATH in NRx Market Share;
V TRx 51,138 vs GL TRx 45,309 & L 659 -- ATH
V NRx 20,400 vs GL NRx 19,044 & L 217 -- ATH
V Refills 30,738 vs GL Refills 26,265 & L 442 -- ATH